Short answer
Septerna, Inc. (SEPN) filed an 8-K current report with the SEC on March 2, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Septerna (SEPN) disclosed material information via Reg FD, with substantive content in Exhibits 99.1 and 99.2.
Septerna, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Septerna (SEPN) disclosed material information via Reg FD, with substantive content in Exhibits 99.1 and 99.2
- "Furnished not filed" status limits legal liability under Exchange Act Section 18: standard for investor presentations and operational updates
- Investors should review Exhibits 99.1 and 99.2 directly for the core disclosed information
Item 8.01 · Other Events
- SEP-631 Phase 1 cleared with adverse event profile comparable to placebo: no severe/serious adverse events across all doses
- Once-daily oral dosing supported by ~24-hour half-life and no food-effect restrictions: strong convenience profile for chronic disease use
- Complete MRGPRX2 inhibition achieved at doses as low as 10 mg QD: clinical proof-of-mechanism established in humans
- Phase 2b trial in chronic spontaneous urticaria (CSU) planned H2 2026, pending completion of long-term toxicology studies
- Pipeline expansion targets atopic dermatitis, interstitial cystitis, migraine, and asthma: broadens addressable market beyond urticaria
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Septerna, Inc. 8-K filings
Get the next SEPN 8-K as it lands
Follow SEPN for push alerts, or ask the research agent what this filing means.